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Abstract
Background: A number of transcription factors coordinate differentiation by simultaneously
regulating gene expression and cell proliferation. CCAAT/enhancer binding protein alpha (C/EBPα )
is a basic/leucine zipper transcription factor that integrates transcription with proliferation to
regulate the differentiation of tissues involved in energy balance. In the pituitary, C/EBPα  regulates
the transcription of a key metabolic regulator, growth hormone.
Results:  We examined the consequences of C/EBPα  expression on proliferation of the
transformed, mouse GHFT1-5 pituitary progenitor cell line. In contrast to mature pituitary cells,
GHFT1-5 cells do not contain C/EBPα . Ectopic expression of C/EBPα  in the progenitor cells
resulted in prolongation of both growth 1 (G1) and the DNA synthesis (S) phases of the cell cycle.
Transcription activation domain 1 and 2 of C/EBPα  were required for prolongation of G1, but not
of S. Some transcriptionally inactive derivatives of C/EBPα  remained competent for G1 and S phase
prolongation. C/EBPα  deleted of its leucine zipper dimerization functions was as effective as full-
length C/EBPα  in prolonging G1 and S.
Conclusion: We found that C/EBPα  utilizes mechanistically distinct activities to prolong the cell
cycle in G1 and S in pituitary progenitor cells. G1 and S phase prolongation did not require that C/
EBPα  remained transcriptionally active or retained the ability to dimerize via the leucine zipper. G1,
but not S, arrest required a domain overlapping with C/EBPα  transcription activation functions 1
and 2. Separation of mechanisms governing proliferation and transcription permits C/EBPα  to
regulate gene expression independently of its effects on proliferation.
Background
Differentiation is commonly associated with intermin-
gled changes in gene expression and cellular proliferation.
In some differentiating cell types, changes in both gene
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transcription and proliferation are regulated by the same
transcription factor [1–9]. CCAAT/Enhancer Binding Pro-
tein alpha (C/EBPα ) is a transcription factor that is re-
quired for the differentiation of a number of tissues [10–
18]. Mice homozygous for C/EBPα  null alleles have severe
defects in tissues involved in metabolic homeostasis [19–
21]. Cellular proliferation is elevated in the liver of these
knockout mice [22] suggesting that C/EBPα  blocks prolif-
eration in vivo. In cultured cells, C/EBPα  expression leads
to decreased colony formation upon antibiotic selection
[23–25], decreased DNA synthesis [22,24–27] and an en-
hanced proportion of cells in the G1 phase of the cell cycle
[26]. Thus, C/EBPα  regulates cellular proliferation, as well
as gene transcription.
C/EBPα  contains a bZIP domain conserved at the carboxy
terminus of a number of transcription factors [12,28]. The
bZIP domain consists of a basic region that binds directly
to DNA, followed immediately by a leucine zipper. C/
EBPα  dimerizes via the leucine zipper. This dimerization
is required for DNA binding [28,29]. At least three tran-
scription activation functions have been described in the
more amino terminal regions of C/EBPα  [30–32]. C/
EBPα  domains and activities associated with proliferation
arrest also have been identified, but vary considerably be-
tween studies [23,25,33–36].
C/EBPα  binds to and activates transcription of the gene
promoter for the p21 inhibitor of cyclin-dependent kinase
(CDK) [37]. This led to speculation that p21 gene activa-
tion may contribute to cell cycle arrest by C/EBPα  [37].
Similarly, suppression of mitotic growth during adipocyte
differentiation was associated with C/EBPα  activation of
the promoters of gadd45 (growth arrest and DNA dam-
age-inducible gene 45), gas2 and gas3 (growth arrest-asso-
ciated genes 2 and 3) [5,6,38,39]. However, C/EBPα
mutants defective in DNA binding still blocked prolifera-
tion [25,33]. This suggested that direct promoter activa-
tion was unnecessary, or redundant, for C/EBPα
proliferation arrest [18].
Possible mechanisms of transcription-independent prolif-
eration arrest by C/EBPα  have been suggested by a
number of studies. Decreased proliferation was associated
with C/EBPα  stabilization of the p21 protein [22,24]. p21
interacted directly with a large internal segment of C/
EBPα  that included transcription activation domain 3
[25] (see Fig. 1A). CDK2 and CDK4 also interacted with
segments of C/EBPα  close to, and within, transcription ac-
tivation domain 3 [36]. CDK2 also interacted with the ba-
sic region of the C/EBPα  [25]. p21 also has a second
interaction site, within the leucine zipper of C/EBPα  [25].
in vitro, C/EBPα  enhanced p21 inhibition of CDK2 activi-
ty. C/EBPα  inhibition of CDK2 activity correlated with
p21 binding to C/EBPα  transcription activation domain 3
[25]. However, proliferation arrest by C/EBPα  still oc-
curred in cell lines not containing p21 genes [40]. This in-
dicated that proliferation arrest by C/EBPα  did not rely
solely upon C/EBPα  enhancement of CDK inhibition by
p21.
Another mechanism reported for proliferation blockage
by C/EBPα  involves the E2F-DP1 transcription complex-
es. E2F complexes activate genes required for entry into S
phase. C/EBPα  binds to and inhibits transcriptional acti-
vation by E2F [26,33]. The complex of E2F with the retin-
oblastoma-related p107 protein is prevalent in cycling
cells. Transcription activation domain 2 of C/EBPα  was
observed to interact specifically with p107 to disrupt
p107/E2F complex formation [34,35]. Disruption of E2F
activity also was associated the basic domain of C/EBPα
[33,34].
Thus, a variety of interactions and mechanisms are poten-
tially involved in proliferation arrest by C/EBPα . This var-
Figure 1
A, Positions of the transcription activation (TA), DNA bind-
ing (basic) and dimerization (ZIP) domains along the linear
sequence of C/EBPα . The numbers below the C/EBPα  dia-
gram indicate the amino acid positions at the boundaries of
the domains. Also shown are C/EBPα  sequences involved in
known actions with the indicated cell-cycle proteins: p107
[34], p21 [25], CDK2 [25,36], CDK4 [36] and E2F [33]. B,
Schematic of the GFP fusions with full-length and mutant C/
EBPα  used in the studies reported here.BMC Cell Biology 2002, 3 http://www.biomedcentral.com/1471-2121/3/6
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iability may indicate divergent mechanisms for the block
of proliferation by C/EBPα  in different study conditions
and/or cell types. In pituitary cells, C/EBPα  is part of a
multi-subunit complex [41,42] that activates the growth
hormone [42] and prolactin [43,44] promoters. Full-
length C/EBPα  is absent from the pituitary progenitor
GHFT1-5 cell line [42,45] in which ectopically expressed
C/EBPα  activates co-transfected growth hormone and
prolactin promoters [42,44,45]. We show here that ectop-
ically expressed C/EBPα  prolongs GHFT1-5 cells in the G1
and S phases of the cell cycle in a transcription-independ-
ent fashion. Different C/EBPα  domains were required for
G1- and S-phase arrest. C/EBPα  domains previously de-
scribed for the interaction with p21 were not required for
arrest in GHFT1-5 cells. Rather, domains previously impli-
cated in the regulation of the E2F and CDK2 pathways by
C/EBPα  were required for arrest of these progenitor cells.
Results
Transcriptionally active and inactive GFP fusions with C/
EBPα
The domains of C/EBPα  and their known interactions
with cell-cycle proteins are summarized in figure 1A. We
conducted studies to determine which, if any, of those ac-
tivities affect the proliferation of GHFT1-5 pituitary pro-
genitor cells. In prior studies, we noticed that fewer cells
were present in GHFT1-5 cell cultures transfected with the
C/EBPα  expression vector than in cultures transfected
with control vectors (X. Wang, F. S., unpublished data).
The decreased cell number might be due to impaired pro-
liferation of GHFT1-5 cells expressing C/EBPα . To exam-
ine if C/EBPα  affected the progression of GHFT1-5 cells
through the cell cycle, we needed to distinguish transfect-
ed cells that expressed C/EBPα  from those that did not.
We fused the cDNA for the green fluorescence protein
(GFP) to either the 5' (GFP-C/EBPα ) or the 3' (C/EBPα -
GFP) end of the coding sequence of the C/EBPα  cDNA.
The cDNAs for the GFP-C/EBPα  and C/EBPα -GFP fusion
proteins were inserted into an expression vector and trans-
fected into GHFT1-5 cells. Flow cytometry was used to
specifically identify green fluorescent, C/EBPα -expressing
cells.
We initially characterized the abilities of the C/EBPα -GFP
and GFP-C/EBPα  fusion proteins to bind DNA and acti-
vate transcription in GHFT1-5 cells (Fig. 2). The C/EBPα -
GFP or GFP-C/EBPα  expression vectors were transfected
into GHFT1-5 cells with a promoter consisting of a single
C/EBPα  binding site upstream of the growth hormone
TATA box. This minimal promoter was specifically re-
sponsive to C/EBPα  expression in GHFT1-5 cells [45,46].
Cells transfected with the C/EBPα -GFP expression vector
showed a statistically significant (p<0.05, n = 5) 9.66 +/-
6.08-fold higher promoter activity than did cells sham-
transfected with the same expression vector deleted of the
C/EBPα  cDNA (Fig. 2A). In contrast, activation by GFP-C/
EBPα  was a statistically insignificant 1.88 +/- 1.48-fold
(Fig. 2A). Promoter activation by C/EBPα -GFP was repro-
ducibly less than promoter activation by unfused C/EBPα .
Western blots of nuclear extracts from the transfected cells
showed that unfused C/EBPα  was expressed at marginally
higher levels (Fig. 2B).
C/EBPα -GFP and GFP-C/EBPα  both were expressed as in-
tact, full-length proteins of the appropriate molecular
weight [45](Fig. 2B, arrow). In addition, both C/EBPα -
GFP and GFP-C/EBPα  bound similarly to DNA (Fig. 2C).
Extracts of cells expressing either C/EBPα -GFP or GFP-C/
EBPα  shifted the electrophoretic mobility of a radiola-
beled oligonucleotide containing a C/EBPα  binding site
(Fig. 2C). No shift was observed with sham-transfected
cells (not shown). The shifted bands were specifically
competed by a 100-fold molar excess of the cold oligonu-
cleotide and were supershifted with an antibody directed
against C/EBPα . GFP-C/EBPα  truncated of its leucine zip-
per (Fig. 1B) was ineffective at shifting the binding site
(Fig. 2C, ∆ LZ). Flow cytometry (discussed later) showed
that comparable levels of green fluorescence were emitted
from cells expressing C/EBPα -GFP, GFP-C/EBPα  and ∆ LZ.
Thus, C/EBPα -GFP and GFP-C/EBPα  were expressed and
could bind to C/EBPα  binding sites in DNA, but differed
in their ability to activate gene transcription.
Cell cycle distribution of GHFT1-5 cells
Transcriptionally active C/EBPα -GFP and transcriptional-
ly inactive GFP-C/EBPα  were compared for their effects on
proliferation of GHFT1-5 cells. We first determined the
distribution of untransfected GHFT1-5 cells in each phase
of the cell cycle. GHFT1-5 cells were grown to subconflu-
ence, collected and the DNA within the cells was stained
with propidium iodide. The DNA content within each cell
was quantified by flow cytometry as the amount of orange
fluorescence from the propidium iodide-stained DNA
(see Materials and Methods for details). The fluorescence
intensity measured from each cell falls into one of three
populations: cells centered around the lowest level of or-
ange fluorescence, cells centered around the highest level
of orange fluorescence which is twice that of the lowest,
and cells with intermediate levels of orange fluorescence.
This corresponds, respectively, to cells containing a 2n
DNA complement prior to duplication of the genome (in
G1 phase), cells containing a 4n DNA complement fol-
lowing genome duplication (in growth phase 2 or in mi-
tosis, G2/M), and cells containing a partially replicated
genome intermediate between 2n and 4n (in S phase). As
averaged from nine independent experiments, the propor-
tion of growing GHFT1-5 cells in G1, S and G2/M corre-
sponded to 42%, 38% and 20%, respectively (Fig 3, white
bars).BMC Cell Biology 2002, 3 http://www.biomedcentral.com/1471-2121/3/6
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We next synchronized GHFT1-5 cells in particular stages
of the cell cycle. GHFT1-5 cells were treated for 20 hours
with nocodazole, which prevents microtubule polymeri-
zation/depolymerization and exit from M phase [47]. The
delivery vehicle, DMSO, was added to parallel cell cul-
tures. Cells also were treated with mimosine (in DMSO),
which blocks cells in late G1 immediately before entry
into S phase [48]. Mimosine also prolongs some cell types
in the S phase itself [48]. GHFT1-5 cells grow with an av-
erage doubling time of approximately 18 to 24 hours. 20
hours of treatment allowed most cells to pass through one
cell cycle and to accumulate as 4n cells upon nocodazole
treatment (Fig. 3, light gray bars) or as 2n cells at the G1/
S boundary upon mimosine treatment (Fig. 3, stippled
gray bars). Thus, GHFT1-5 cells can be synchronized at
particular stages of the cell cycle. Synchronization facili-
tated characterization of the cell cycle stages blocked or
prolonged by C/EBPα  expression.
Transcriptionally active and inactive C/EBPα  both retain 
GHFT1-5 cells in the G1 and S phases of the cell cycle
We determined if either C/EBPα -GFP or GFP-C/EBPα  al-
tered the distribution of GHFT1-5 cells in the G1, S or G2/
M phases of the cell cycle. GHFT1-5 cells were transfected
with the expression vectors for C/EBPα -GFP or GFP-C/EB-
Pα , or with the sham expression vector not containing the
C/EBPα  cDNA. The cells were incubated for one day to al-
low time for C/EBPα  expression. Cells were then synchro-
nized in M-phase or in G1/S by 20-hour incubations with
nocodazole (Fig. 4A) or mimosine (Fig. 4B). Cells were
collected and stained with propidium iodide. Flow cytom-
etry was used to measure DNA content in 1) cells trans-
fected with the sham expression vector (Fig. 4, Sham), 2)
green fluorescent cells expressing GFP-tagged C/EBPα
(Fig. 4, C/EBPα -GFP or GFP-C/EBPα ) or 3) the subpopu-
lation of cells from the C/EBPα -GFP or GFP-C/EBPα
transfections that did not express measurable amounts of
green fluorescent C/EBPα  (Fig. 4, No C/EBP). The "No C/
EBP" cells represent an internal control for cells not ex-
pressing C/EBPα  collected simultaneously with cells ex-
pressing C/EBPα . The No C/EBP controls also indicated
the extent to which green fluorescent, C/EBPα -expressing
cells were distinguished from non-expressing cells by flow
cytometry. For all our experiments, the distribution of
cells in the G1, S and G2/M phases was similar for the "No
C/EBPα  " and sham-transfected cells.
The expression of C/EBPα -GFP or GFP-C/EBPα  resulted in
a statistically significant decrease in the amount of cells
blocked in G2/M upon nocodazole treatment compared
to sham-transfected cells (Fig. 4A) (p << 0.01, n = 6). This
indicated that C/EBPα  expression prevented a significant
proportion of GHFT1-5 cells from reaching G2/M to be
blocked by nocodazole. When cells were blocked in G1 by
mimosine treatment, C/EBPα  expression caused no de-
Figure 2
A, Chloramphenicol acetyltransferase activity expressed
from a promoter transiently transfected into GHFT1-5 cells
together with vectors expressing C/EBPα , fused or not, with
GFP. The promoter contained a single C/EBPα  binding site
upstream of a TATA box [45]. CAT activities were normal-
ized to the activity present in cells transfected with the
expression vector not containing the C/EBPα  cDNA
("Sham") and plotted as the mean +/- standard deviation from
five independent experiments. B, Nuclear extracts from
sham-transfected cells and cells expressing C/EBPα , C/EBPα -
GFP and GFP-C/EBPα  were separated by SDS-polyacryla-
mide gel electrophoresis. The separated proteins were trans-
ferred to a membrane and stained with an antibody directed
against the FLAG epitope, which was appended to the amino
terminus of C/EBPα  in all the constructs. Arrow, expressed
C/EBPα -GFP and GFP-C/EBPα . C, Whole cell extracts, from
cells transfected with C/EBPα -GFP and GFP-C/EBPα  or GFP-
C/EBPα∆ LZ expression vectors, were incubated with a radi-
olabeled oligonucleotide containing a high affinity consensus
C/EBPα  binding site. The observed complexes were com-
peted with a 1, 10 and 100 fold molar excess of unlabeled oli-
gonucleotide or were supershifted with an antibody directed
against C/EBPα .BMC Cell Biology 2002, 3 http://www.biomedcentral.com/1471-2121/3/6
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crease in the proportion of cells in G2/M (Fig. 4B). This
demonstrated that C/EBPα  expression did not actively de-
crease the proportion of cells in G2/M.
The C/EBPα -induced reduction in cells blocked in G2/M
was associated with a highly statistically significant in-
crease in the proportion of GHFT1-5 pituitary progenitor
cells in G1 (p < 0.001) and a statistically significant in-
crease in the proportion of cells in S phase (p < 0.03) (Fig.
4A). This retention of GHFT1-5 cells in the G1 and S phas-
es of the cell cycle occurred for both the transcriptionally
active C/EBPα -GFP and inactive GFP-C/EBPα  fusions. The
independence of C/EBPα -induced proliferation arrest
from C/EBPα -regulated transcriptional activation also has
been observed in other studies [25,26]. Thus, simple tran-
scription activation mechanisms do not account for the
effect of C/EBPα  on the cell cycle.
Targeting of C/EBPα  to the presumed centromeric G1/S 
checkpoint is insufficient for prolongation of G1
Our prior fluorescence microscopy studies showed that C/
EBPα -GFP, GFP-C/EBPα , and antibody-stained C/EBPα
[45,46], concentrated at specific intranuclear domains in
GHFT1-5 cells (see Fig. 5A, GFP-C/EBPα ). These domains
coincide with regions that stain with the blue fluorescent
DNA-binding dye Hoechst 33342 (Fig. 5A, Hoechst
33342). Hoechst 33342 stains AT-rich DNA that concen-
trates around the centromeres [45,49]. Given the role of
the centromere as a checkpoint for regulation of the mi-
totic phase of the cell cycle [50,51], it was hypothesized
that C/EBPα  localization around the centromere could
play a role in C/EBPα  regulation of the cell cycle [49].
To investigate if targeting of C/EBPα  to the peri-centro-
meric chromatin is necessary or sufficient to cause G1 and
S phase prolongation in GHFT1-5 cells, we first deter-
mined the domain of C/EBPα  required to target C/EBPα
to the peri-centromeric chromatin. It was previously sug-
gested that the peri-centromeric targeting of C/EBPα  was
a function of DNA binding: C/EBPα  binding sites are con-
centrated within the repeated DNA sequences that com-
prise the bulk of peri-centromeric chromatin [49]. Indeed,
C/EBPα  truncated to contain little more than the DNA
binding, bZIP domain still concentrated at peri-centro-
meric chromatin [45]. By contrast, C/EBPα  deleted of
amino acids 310 to 358 (Fig. 1B, ∆ LZ) no longer targeted
to the peri-centromeric DNA (Fig. 5B). This deletion dis-
rupts DNA binding (Fig. 2C) by eliminating the leucine
zipper required for DNA binding by all members of the
bZIP family of transcription factors [52]. Thus, as predict-
ed [49], the bZIP domain is necessary and sufficient for C/
EBPα  targeting to peri-centromeric chromatin.
When expressed in GHFT1-5 cells, ∆ LZ was as effective as
full-length GFP-C/EBPα  in prolonging both G1 and S
(Fig. 6A). Thus, leucine zipper dimerization, site-specific
DNA binding and targeting of C/EBPα  to peri-centromeric
were not required for C/EBPα  prolongation in G1 and S.
In contrast, the isolated C/EBPα  bZIP DNA binding do-
main (Fig. 1B, DBD), which still targeted to peri-centro-
meric chromatin, did not prolong G1 (Fig. 6B). S phase
remained prolonged upon DBD expression. The different
effects of the isolated DBD on G1 and S blockage indicat-
ed that C/EBPα  regulation of G1 and S phase arrest was
mechanistically distinct. Thus, C/EBPα  regulates prolifer-
ation by two distinct pathways. Both pathways do not de-
pend upon site-specific DNA binding, which is commonly
considered a prerequisite for gene-specific transcription.
Prolongation in G1 requires the amino terminal domain of 
C/EBPα
The C/EBPα  DBD therefore was insufficient for prolonga-
tion of G1 (Fig. 6B). We next determined which addition-
al domains of C/EBPα  were required for G1 prolongation.
C/EBPα  amino acids 1–154 or 154–257 were appended
to the DBD (see Fig. 1B). The addition of amino acids 1–
154 (Fig. 7, DBD + 1–154) caused a statistically significant
increase, relative to sham-transfected cells, in the propor-
tion of cells in G1 (p << 0.01, n = 6). The proportion of
cells in G1 was not statistically different in cells expressing
DBD + 1–154 from that in cells expressing full-length C/
Figure 3
GHFT1-5 cells were grown to subconfluence and treated for
20 hours with DMSO (white bars), 100 ng/ml nocodazole
(gray bars) or 0.5 mM mimosine (speckled gray bars), both in
DMSO. The amount of DNA within each cell was measured
by flow cytometric quantification of the orange fluorescence
emitted from propidium iodide-stained DNA. The propor-
tion of GHFT1-5 cells containing a 2n complement of DNA
(G1), a 4n complement of DNA (G2/M), and an intermediate
amount of DNA (S) was determined for each treatment and
presented as the mean +/- standard deviation from nine inde-
pendent experiments.BMC Cell Biology 2002, 3 http://www.biomedcentral.com/1471-2121/3/6
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EBPα -GFP. Adding amino acids 1–125, instead of amino
acids 1–154, caused a similar prolongation in G1 (Fig. 7,
DBD + 1–125). Thus, an element in the amino terminal
domain of C/EBPα  was required for G1 prolongation.
In contrast, addition of amino acids 154–257 to C/EBPα
DBD did not rescue G1 prolongation (Fig. 7, DBD + 154–
257). Again, appending amino acids 1–125 to this mutant
restored G1 prolongation (A126–153), as did amino acids
1–97 (A 98–153). All of the mutants contained the DBD
and prolonged the cell cycle in S phase (Fig. 7). Thus, the
DNA binding, bZIP domain was sufficient to direct S
phase regulation by C/EBPα  whereas amino acids 1–97
contained a domain required for G1 regulation.
Discussion
C/EBPα  prolongs GHFT1-5 cells in G1 and S
The differentiative and anti-mitotic actions of C/EBPα
have been observed in a variety of cell culture models
[23,24,26,40,53]. To date, studies of the C/EBPα  block of
proliferation have relied on comparing the growth [23–
25,40] or DNA synthetic [22,24–27] rates of C/EBPα -ex-
pressing and non-expressing cells. These studies suggest
that multiple, possibly independent, mechanisms may
contribute to C/EBPα  arrest in a variety of cells [18,23–
26,33–37,40,54–56]. Studies that distinguish the anti-
proliferative actions of C/EBPα  at different phases of the
cell cycle, and in specific cell types, may clarify these dis-
crepancies.
Our studies showed that C/EBPα  expression prolonged
the proliferation of GHFT1-5 pituitary progenitor cells at
two different phases of the cell cycle, G1 and S (Fig. 4). A
G1 block has been reported previously in C/EBPα -ex-
pressing mouse L cells [26]. However, those studies did
not define the activities within C/EBPα  required for that
blockage. Here, we observed that prolongation in G1 re-
quired the amino terminal 97 amino acids of C/EBPα
(Fig. 7.). In contrast, amino acids 1 to 97 were not re-
quired for S phase arrest (Figs. 6, 7). This showed that C/
EBPα  prolongation of GHFT1-5 cells in the G1 and S
phases occurred through molecularly distinct pathways.
Such distinct effects on G1 and S may contribute to the
wide variations in mechanisms reported, to date, to partic-
ipate in proliferation arrest by C/EBPα .
Cell Cycle Proteins and C/EBPα  Inhibition of Proliferation
Candidate mechanisms for the block of proliferation by
C/EBPα  include 1) activation of the gene promoters of the
cyclin-dependent kinase inhibitor p21 [37], gadd45 [5,6],
gas2 and gas3 [38,39], 2) post-transcriptional stabiliza-
tion of p21 [22], or 3) interactions of C/EBPα  with cell cy-
cle proteins including p21 [22,24,25,55], CDK2 [25,36],
CDK4 [36], retinoblastoma [54], the retinoblastoma-re-
lated protein p107 [34] and the G1/S-regulating E2F tran-
scription complex [26,33] (Fig. 1A). We found that
transcriptional activation domain 3 and the leucine zip-
per were not required for prolongation of either G1 or S
(Fig 7). These domains interact with p21, CDK2 and
CDK4 [22,24,25,36,55]. Thus, C/EBPα  interactions with
at least p21 and CDK4 were not required for the anti-pro-
liferative actions of C/EBPα  in GHFT1-5 cells. CDK2, and
other proteins, also interact with another domain of C/
EBPα  [25] required for proliferation arrest (discussed be-
low).
Figure 4
Cells were transfected with the control expression vector
(Sham), the transcriptionally active C/EBPα -GFP expression
vector or the transcriptionally inactive GFP-C/EBPα  expres-
sion vector and treated one day later with A, nocodazole or
B, mimosine. Cells from the transfections with the C/EBP-
GFP and GFP-C/EBP expression vectors were separated into
cells with green fluorescence above background levels (C/
EBP-GFP and GFP-C/EBP) or at background (No C/EBP).
The proportion of cells in the G1, S and G2/M phases were
plotted as the mean +/- standard deviation from A, six or B,
three independent experiments. Statistically significant differ-
ences in the proportion of cells in G1, S or G2/M, relative to
the proportions determined for the sham-transfected cells,
are indicated (one-way ANOVA: **, p < 0.01; *p < 0.05; -, no
difference).BMC Cell Biology 2002, 3 http://www.biomedcentral.com/1471-2121/3/6
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Arrest in S phase was associated with amino acids 259 to
310 (Fig. 6), which include the basic amino acid-rich,
DNA binding region of C/EBPα . C/EBPα  deleted of the
leucine zipper dimerization domain, also required for
DNA binding [25] (Fig. 2C), was as effective as full-length
GFP-C/EBPα  in prolonging both S and G1 (Fig. 6A). Thus,
DNA binding per se was not required for proliferation ar-
rest. The basic region of C/EBPα  blocks the transcriptional
activity of E2F by unknown mechanisms [33] and con-
tains another known CDK2-interaction site [25]. Either of
these activities may contribute to basic region-dependent,
S phase arrest of GHFT1-5 cell proliferation.
G1 block in GHFT1-5 cells required C/EBPα  amino acids
1–97 (Fig. 7), comprising activation domains 1 and 2
[31]. Amino acids 1 to 97 have been implicated in C/EBPα
growth arrest via the E2F/pl07 complexes [34,35]. C/
EBPα  interaction with p107 is believed to prevent the for-
mation of an S-phase promoting complex containing
p107 and E2F [26,34,35]. Thus, G1 block in GHFT1-5
cells may be related to the ability of C/EBPα  to interact
with p107. However, the amino terminus of C/EBPα  also
functionally interacts with a number of other factors
[31,45,46], any of which might contribute to proliferation
arrest.
Subnuclear Architecture and C/EBPα  Inhibition of Prolifer-
ation
Tang and Lane [49] showed that C/EBPα  becomes associ-
ated with peri-centromeric chromatin upon expression
during adipocyte differentiation. We observed that C/EB-
Pα , expressed in mouse pituitary progenitor GHFT1-5
cells, also localized to peri-centromeric chromatin [45].
Here we show that targeting of C/EBPα  to peri-centromer-
ic chromatin in GHFT1-5 cells required the DNA binding
domain of C/EBPα  (Fig. 5). However, C/EBPα  deleted of
the DNA binding domain was as effective as full-length C/
EBPα  in prolonging GHFT1-5 cells in the G1 and S phases
of the cell cycle (Fig. 6A). Thus, the specific association of
C/EBPα  with peri-centromeric chromatin, speculated to
contribute to C/EBPα  growth arrest [49], was not neces-
sary for disruption of the cell cycle by C/EBPα . The inde-
pendence of C/EBPα  regulation of proliferation from its
intranuclear localization may even be necessary since we
have recently determined that pituitary cell differentiation
is associated with the dispersal of C/EBPα  from peri-cen-
tromeric heterochromatin by the pituitary-specific tran-
scription factor Pit-1 (J. F. E., M. A. Kawecki, F. S., R. N. D.,
submitted).
Transcription-Independent Inhibition of Proliferation
Transcription factors, like C/EBPα , may regulate cell pro-
liferation by directly controlling the expression of pro-
teins required for cell cycle progression. Indeed, C/EBPα
activates transcription of the p21 [37], gadd45 [5,6], gas2
and gas3 [38,39] genes. However, similar levels of p21
mRNA in the livers of wild-type and homozygous C/EBPα
knock-out mice [22] argue against a physiologically signif-
icant contribution of C/EBPα  to p21 gene transcription in
the liver. We also observed that transcriptionally inactive
and DNA-binding-defective forms of C/EBPα  still blocked
GHFT1-5 cell proliferation in both the G1 and S phases of
the cell cycle (Figs. 2, 4,6). DNA-binding-defective mu-
tants of C/EBPα  have also been observed to block prolif-
eration in other cell lines [25,33]. Together, this suggests
that C/EBPα  regulation of transcription, in general, might
not contribute to the regulation of cell proliferation. It re-
mains possible that C/EBPα  activation of the transcription
of some cell cycle regulatory genes does control prolifera-
tion in some cell types or under certain conditions [8,37–
39,56].
The absence of a dependence of GHFT1-5 cell prolifera-
tion on transcription factor activities that are more classi-
cally associated with transcription regulation strongly
Figure 5
A, GFP-C/EBP or, B, GFP-C/EBP deleted of amino acids 310
to 358 (∆ LZ) were expressed in GHFT1-5 cells. The ∆ LZ
construct is depicted in figure 1B. The transfected cells were
counter-stained with the blue fluorescent, DNA-binding dye
Hoechst 33342 immediately before analysis by fluorescence
microscopy. Green fluorescent (left panels) and blue fluores-
cent (right panels) images were collected from a single cell
using filter sets that selectively discriminate GFP and Hoechst
33342 fluorescence (see Materials and Methods). The subnu-
clear position of GFP-C/EBPα  and ∆ LZ were compared to
the subnuclear position of the peri-centromeric chromatin
stained by Hoechst 33342. Representative images are shown.BMC Cell Biology 2002, 3 http://www.biomedcentral.com/1471-2121/3/6
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suggests that C/EBPα , and perhaps other transcription fac-
tors, control proliferation and transcription through com-
pletely separable pathways. The effects of human
papilloma virus E7 proteins on C/EBPα -induced differen-
tiation and growth arrest also suggest that the effects of C/
EBPα  on proliferation are mechanistically divergent [40].
Having distinct mechanisms for regulation of gene tran-
scription and proliferation allows a transcription factor to
regulate these two critical processes completely independ-
ently of one another. This may be particularly important
in differentiated, non-proliferating cells in which events
that regulate a transcription factor's contribution to gene
expression must be disconnected from that transcription
factor's continuing blockage of proliferation.
Conclusions
C/EBPα  is a transcription factor that controls both prolif-
eration and gene expression. C/EBPα  uses molecularly
distinct mechanisms to prolong the G1 and S phases of pi-
tuitary progenitor GHFT1-5 cells. The anti-proliferative ef-
fects of C/EBPα  do not require activities in C/EBPα
commonly required for gene-specific transcription. Prolif-
eration arrest instead corresponds with C/EBPα  domains
previously implicated in post-transcriptional effects on
E2F and/or CDK2 activity.
Materials and Methods
Plasmid construction
The GFP-C/EBPα  vector was constructed by inserting the
cDNA encoding the S65T derivative of GFP [57] at the
start codon of the cDNA encoding rat C/EBPα . The fused
cDNA was cloned into a previously described expression
vector [58]. The GFP and C/EBPα  portions of the fusion
were separated by a 16 amino acid long linker including
the epitope for the FLAG antibody. The C/EBPα -GFP vec-
tor was constructed by inserting the S65T GFP into the
NcoI site present near the carboxy terminus of rat C/EBPα
(also tagged at the amino terminus with the FLAG
epitope) in our previously described C/EBPα  expression
vector [42]. This resulted in a deletion of the last four ami-
no acids of C/EBPα . The DBD and DBD + 154–257 deriv-
atives of C/EBPα  were constructed by replacing,
respectively, the amino terminal 257 amino acids of C/
EBPα -GFP (to the SgrAI site of C/EBPα ) and the amino
terminal 153 amino acids of C/EBPα -GFP (to the NotI site
of C/EBPα ) with oligonucleotides containing a strong Ko-
zak sequence. DBD + 1–154 was constructed by replacing
amino acids 155 to 257 (from the NotI to SgrAI sites) with
an oligonucleotide. The remaining constructs (Fig. 7)
were generated by appending C/EBPα  fragments to the
NotI site of DBD + 1–154, or to the SgrAI site of DBD. ∆ LZ
was constructed by deleting amino acids from amino acid
310 (Tth111II site) at the junction of the basic region and
leucine zipper of C/EBPα  to the carboxy terminus of the
GFP-C/EBPα  fusion. The C/EBP-TATA reporter used to de-
termine the transcriptional activity of the two GFP fusion
proteins was previously described [45].
Transfection
GHFT1-5 cells were propagated at 37°C and 5% CO2 in
Dulbecco's modified Eagle (DME-H21) medium supple-
Figure 6
GHFT1-5 cells were transfected with the A, Sham, GFP-C/
EBP and ∆ LZ expression vectors or B, Sham, C/EBP-GFP
and DBD expression vectors and treated with nocodazole.
The proportions of cells in G1, S and M phase were deter-
mined and plotted as the mean +/- standard deviation from
six independent experiments for both A and B. No C/EBP,
the subpopulation of cells with background levels of green
fluorescence (i.e. did not express GFP-linked C/EBPα ). Data
from No C/EBP cells are shown adjacent to the green fluo-
rescent cells for each expression construct. Statistically sig-
nificant differences in the proportion of green fluorescent
cells in G1, S or G2/M, relative to the proportions deter-
mined for the sham-transfected cells, are indicated (One-way
ANOVA: **, p < 0.01; *p < 0.05; -, no difference).BMC Cell Biology 2002, 3 http://www.biomedcentral.com/1471-2121/3/6
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mented with 10% fetal calf serum. Approximately 1 ×  107
cells were transfected by electroporation, as previously de-
scribed [42], with 5 µg of either the C/EBPα -GFP, GFP-C/
EBPα , or control expression vectors. Following transfec-
tion, cells were propagated at 33°C. Incubation at 33°C re-
sults in significantly higher levels of green fluorescence
(unpublished data), presumably because of better folding
of the jellyfish GFP. Transfected cells were maintained in
the dark throughout the experiment to minimize fluores-
cence activation of GFP prior to flow cytometry.
DNA Binding and Promoter Activation
Electrophoretic mobility shifts assays were done by mix-
ing a radiolabeled oligonucleotide containing a consen-
sus, high affinity C/EBP binding site
(GATCGAGCCCCATTGCGCAATCATAGATC) together
with extracts prepared from transfected cells as previously
described [58,59]. Competition with the same, unlabeled
oligonucleotide in 1, 10 or 100 molar excess of the radi-
olabeled probed indicated specific binding. The protein
DNA complex was supershifted with an antibody directed
against C/EBPα  (Santa Cruz Biotechnology, sc-61). For
studies of the transcriptional activation properties of the
fusion proteins, 1 µg of the C/EBP-TATA vector [45] was
co-transfected and transcriptional activity was assessed by
measuring the amount of chloramphenicol acetyltrans-
ferase reporter expressed with and without C/EBPα  ex-
pression [45].
Fluorescence Microscopy
Following transfection, most cells were plated into 14 cm
dishes and allowed to grow for 24 hours. This ensured
that the cells were not confluent by the time of collection
for cell cycle analysis. A small portion of the transfected
cells were cultivated on a 22 ×  22 mm No. 1 borosilicate
glass cover slip in a separate 6-well dish and treated with
nocodazole, mimosine or vehicle alone as described be-
low. The coverslips were removed for fluorescence micro-
scopic observation immediately before collecting cells for
flow cytometric analysis of DNA content and GFP expres-
sion. Cells were stained 10–20 minutes with 5 µg/ml of
the cell-permeable DNA binding dye Hoechst 33342. The
green fluorescence emitted from C/EBPα  tagged with GFP
and the blue fluorescence emitted from Hoechst 33342-
stained DNA were readily distinguished by selectively ex-
citing each fluorophore and capturing fluorescence emis-
sions specific for each fluorophore using appropriate
excitation and emission filter sets (Chroma Technology
Corporation, Brattelboro, VT)[45]. The images shown in
Fig. 5 were acquired using an Olympus 40X PlanApochro-
mat (0.95 numerical aperture) objective on an Olympus
IX-70 microscope. Metamorph acquisition software (Uni-
versal Imaging Corporation, Downingtown, PA) on an
Orca cooled interline camera (Hamamatsu, Bridgewater,
NJ) were used to collect the images.
Post-transfection Cell Synchronization
The C/EBPα  fusion proteins were expressed for one day
following transfection, after which we added to the cell
culture media 100 ng/ml nocodazole (Sigma) in dimeth-
ylsulphoxide (DMSO), 0.5 mM mimosine (Sigma) in
DMSO, or DMSO vehicle. In some experiments, cells were
also grown for 48 and 72 hours post-transfection before
applying nocodazole (data not shown). The distributions
of cells in G1, S and G2/M, in the presence or absence of
C/EBPα  expression, were similar for cells grown for 24 (re-
ported here), 48 or 72 hours (data not shown) prior to
nocodazole addition. Following nocodazole, mimosine
or DMSO addition, the transfected GHFT1-5 cells contin-
ued to be cultivated at 33°C.
Flow Cytometry
24 hours after drug or vehicle treatment, transfected cells
were trypsinized, collected in DME-H21 media contain-
ing 10% fetal calf serum, and washed twice with PBS. The
harvested cells (typically 5 ×  106 to 1 ×  107 cells) were re-
suspended in 300 µl of 8 µg/ml propidium iodide (Molec-
ular Probes) in PBS containing 0.1% NP-40 and 10 µg/ml
RNAse A, then incubated at room temperature in the dark
for 30 minutes. The cell suspension was then analyzed on
a FACScan flow cytometer (Becton Dickinson) at a flow
Figure 7
The indicated amino acids of C/EBPα  were appended to
DBD-GFP (see Fig. 1B) and expressed in GHFT1-5 cells. The
proportions of green fluorescent cells in G1, S and M phase
in nocodazole-treated cells were determined and plotted as
the mean +/- standard deviation from three independent
experiments. The DBD + 1–154 mutant was repeated a total
six times (not shown), for which the statistical significance
remained p < 0.01. Statistically significant increases in the
proportion of G1 cells, compared to Sham cells, are indi-
cated (One-way ANOVA: **, p < 0.01; *p < 0.05; -, no differ-
ence).BMC Cell Biology 2002, 3 http://www.biomedcentral.com/1471-2121/3/6
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rate of 12 µl/min. Fluorescence of the GFP and propidium
iodide-bound DNA was excited with a 488 nm argon-ion
laser. Green GFP fluorescence was collected using a 530/
30-nm band pass filter, and orange emission from propid-
ium iodide-bound DNA was detected using a 585/42-nm
band pass filter. Photomultiplier tube voltage and spectral
compensation were initially set using single-stained cells
(cells expressing GFP fusions with C/EBPα  but not stained
with propidium iodide and cells transfected with the con-
trol vector containing no GFP cDNA but stained with pro-
pidium iodide). Electronic compensation was adjusted
among the fluorescence channels to remove residual spec-
tral overlap. The area and width of each event were meas-
ured to discriminate intact single cells from debris and
from doublet or multiple cells stuck together. GFP fluores-
cence and propidium iodide-stained DNA fluorescence
was thus collected from single cells. A minimum of
10,000 cellular events was collected for each sample. Data
was analyzed using CELLQuest software (Becton Dicken-
son), and cell cycle subset analyses of DNA histograms
were performed using ModFitLT™ software (Verity Soft-
ware House, Topsham, ME).
Statistical Analysis
One-way analysis of variance was used to compare data
from multiple independent experiments. Statistically sig-
nificant differences (**, p < 0.01; *, p < 0.05 compared to
the Sham-transfected cells) and experiment number are
indicated in the figures and legends. All significant differ-
ences were confirmed by paired, one-tailed t-tests.
List of abbreviations
C/EBPα  CCAAT/Enhancer Binding Protein alpha
G1 Growth phase 1 of the cell cycle
S DNA Synthesis phase of the cell cycle
G2 Growth phase 2 of the cell cycle
M Mitsosis phase of the cell cycle
CDK Cyclin-Dependent Kinase
GFP Green Fluorescent Protein
GFP-C/EBPα  Fusion protein with GFP attached to the
amino terminus of C/EBPα
C/EBPα -GFP Fusion protein with GFP attached to the car-
boxy terminus of C/EBPα
∆  Symbol signifying "deletion" when naming constructs
LZ Leucine Zipper
DBD DNA Binding Domain
DMSO Dimethyl Sulfoxide
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